Literature DB >> 10517355

Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatography-electrospray mass spectrometry.

Y G Shin1, K H Cho, S M Chung, J Graham, T K Das Gupta, J M Pezzuto.   

Abstract

A rapid and sensitive high-performance liquid chromatography-electrospray MS method has been developed to determine tissue distribution of betulinic acid in mice. The method involved deproteinization of these samples with 2.5 volumes (v/w) of acetonitrile-ethanol (1:1) and then 5 microl aliquots of the supernatant were injected onto a C18 reversed-phase column coupled with an electrospray MS system. The mobile phase employed isocratic elution with 80% acetonitrile for 10 min; the flow-rate was 0.7 ml/min. The column effluent was analyzed by selected ion monitoring for the negative pseudo-molecular ion of betulinic acid [M-H]- at m/z 455. The limit of detection for betulinic acid in biological samples by this method was approximately 1.4 pg and the coefficients of variation of the assay (intra- and inter-day) were generally low (below 9.1%). When athymic mice bearing human melanoma were treated with betulinic acid (500 mg/kg, i.p.), distribution was as follows: tumor, 452.2 +/- 261.2 microg/g; liver, 233.9 +/- 80.3 microg/g; lung, 74.8 +/- 63.7 microg/g; kidney, 95.8 +/- 122.8 microg/g; blood, 1.8 +/- 0.5 microg/ml. No interference was noted due to endogenous substances. These methods of analysis should be of value in future studies related to the development and characterization of betulinic acid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10517355     DOI: 10.1016/s0378-4347(99)00291-1

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  9 in total

Review 1.  Mitochondrial metabolism inhibitors for cancer therapy.

Authors:  Emma E Ramsay; Philip J Hogg; Pierre J Dilda
Journal:  Pharm Res       Date:  2011-09-15       Impact factor: 4.200

2.  Co-administration of betulinic acid and methamphetamine causes toxicity to dopaminergic and serotonergic nerve terminals in the striatum of late adolescent rats.

Authors:  Bryan Killinger; Mrudang Shah; Anna Moszczynska
Journal:  J Neurochem       Date:  2013-12-03       Impact factor: 5.372

3.  Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity.

Authors:  Praveen Rajendran; Manu Jaggi; Manoj K Singh; Rama Mukherjee; Anand C Burman
Journal:  Invest New Drugs       Date:  2007-09-13       Impact factor: 3.850

4.  NOXA as critical mediator for drug combinations in polychemotherapy.

Authors:  H Ehrhardt; I Höfig; F Wachter; P Obexer; S Fulda; N Terziyska; I Jeremias
Journal:  Cell Death Dis       Date:  2012-06-21       Impact factor: 8.469

5.  Mcl-1 protects prostate cancer cells from cell death mediated by chemotherapy-induced DNA damage.

Authors:  Teresita Reiner; Alicia de Las Pozas; Ricardo Parrondo; Deanna Palenzuela; William Cayuso; Priyamvada Rai; Carlos Perez-Stable
Journal:  Oncoscience       Date:  2015-09-01

6.  Betulinic Acid for cancer treatment and prevention.

Authors:  Simone Fulda
Journal:  Int J Mol Sci       Date:  2008-06-27       Impact factor: 6.208

7.  Betulinic acid selectively increases protein degradation and enhances prostate cancer-specific apoptosis: possible role for inhibition of deubiquitinase activity.

Authors:  Teresita Reiner; Ricardo Parrondo; Alicia de Las Pozas; Deanna Palenzuela; Carlos Perez-Stable
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

8.  A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex).

Authors:  Sebastian Jäger; Melanie N Laszczyk; Armin Scheffler
Journal:  Molecules       Date:  2008-12-18       Impact factor: 4.411

9.  Anti-Proliferative Activity of Triterpenoids and Sterols Isolated from Alstonia scholaris against Non-Small-Cell Lung Carcinoma Cells.

Authors:  Chao-Min Wang; Kuei-Lin Yeh; Shang-Jie Tsai; Yun-Lian Jhan; Chang-Hung Chou
Journal:  Molecules       Date:  2017-12-01       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.